title: Drug-resistant tuberculosis in Central Mozambique: the role of a rapid genotypic susceptibility testing.
abstract: Genotypic molecular testing may be very helpful for tuberculosis (TB) drug-resistance surveillance and for treatment guidance in low resource settings.
  
  
  
  Descriptive analysis of M. tuberculosis isolates from Beira Central Hospital, Mozambique, during 2014-2015. Genotype MTBDRplus and MTBDRsl were used and patient medical records reviewed. To explore genotypic susceptibility profile of Mycobacterium tuberculosis, to first and second line drugs (SLD) in Beira Mozambique.
  
  
  
  Of 155 isolates, 16.1 % (25) were multidrug resistant (MDR), 8.4 % (13) isoniazid-monoresistant and 1.3 % (2) rifampicin-monoresistant. Among MDR-TB, 22.2 % showed primary and 77.8 % represented acquired resistance. The majority of patients with drug resistance had a history of previous TB treatment. Among 125 isolates tested for ethambutol and SLD, 7.2 % (9) were resistant to ethambutol, 4.8 % (6) to fluoroquinolones and 0.8 % (1) to ethambutol and fluoroquinolones. Resistance to injectable SLD was not detected.
  
  
  
  As far as we know this is the first report of a genotypic testing used to provide information about SLD resistance in Mozambique, where phenotypic susceptibility testing is usually unavailable. Extensively drug resistant TB was not detected in this isolates from Beira Mozambique.
authors.affiliation: School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.|Faculdade de Ciências de Saúde da Universidade Católica de Moçambique, Beira, Mozambique.
authors.forename: Evangelina Inácio
authors.initials: EI
authors.lastname: Namburete
authors.affiliation: Laboratório de Referencia de tuberculose, Hospital Central da Beira, Moçambique, Beira, Mozambique.
authors.forename: Inês
authors.initials: I
authors.lastname: Tivane
authors.affiliation: Laboratório de Referencia de tuberculose, Hospital Central da Beira, Moçambique, Beira, Mozambique.
authors.forename: Miguelhete
authors.initials: M
authors.lastname: Lisboa
authors.affiliation: Laboratório de Microbactérias do HCFMRP, USP, Ribeirão Preto, Brasil.
authors.forename: Margarida
authors.initials: M
authors.lastname: Passeri
authors.affiliation: Laboratório de Microbactérias do HCFMRP, USP, Ribeirão Preto, Brasil.
authors.forename: Renata
authors.initials: R
authors.lastname: Pocente
authors.affiliation: Faculdade de Ciências de Saúde da Universidade Católica de Moçambique, Beira, Mozambique.
authors.forename: Josefo Joao
authors.initials: JJ
authors.lastname: Ferro
authors.affiliation: Infectious Diseases Epidemiology Research Unit, University of Pittsburgh, Pittsburgh, USA.
authors.forename: Lee H
authors.initials: LH
authors.lastname: Harrison
authors.affiliation: School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. vbollela@gmail.com.|Internal Medicine Department, Hospital das Clínicas School of Medicine of Ribeirão Preto, University of São Paulo, Avenida Bandeirantes 3900, Monte Alegre, 14049-900, Ribeirão Preto, São Paulo, Brazil. vbollela@gmail.com.
authors.forename: Valdes Roberto
authors.initials: VR
authors.lastname: Bollela
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial / Q000187:drug effects* / Q000235:genetics; D004977:Ethambutol / Q000627:therapeutic use; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use; D005838:Genotype; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests; D009073:Mozambique; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics* / Q000302:isolation & purification; D012293:Rifampin / Q000627:therapeutic use; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000382:microbiology*; D014397:Tuberculosis, Pulmonary / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents; D024841:Fluoroquinolones; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin
keywords: Molecular diagnosis; Mozambique; Tuberculosis